Literature DB >> 3463532

The myoblast defect identified in Duchenne muscular dystrophy is not a primary expression of the DMD mutation. Clonal analysis of myoblasts from five double heterozygotes for two X-linked loci: DMD and G6PD.

C Webster, G Filippi, A Rinaldi, C Mastropaolo, M Tondi, M Siniscalco, H M Blau.   

Abstract

We previously proposed the hypothesis that the primary expression of the defect in X-linked Duchenne muscular dystrophy (DMD) occurred in the myoblast, or muscle precursor cell. This was based on the observation that the number of viable myoblasts obtained per gram DMD muscle tissue was greatly reduced and those that grew in culture had decreased proliferative capacity and an aberrant distended flat morphology. Here we test that hypothesis by determining whether the expression of the myoblast defect is X-linked. Muscle cells were obtained from five doubly heterozygous carriers of two X-linked loci, DMD and glucose-6-phosphate dehydrogenase (G6PD), and compared with those from five sex- and age-matched controls heterozygous for G6PD only. A total of 1,355 individual clones were determined to be muscle and evaluated at the single cell level for proliferative capacity, morphology, and G6PD isozyme expression. The results demonstrate that the proportion of defective myoblast clones is significantly increased in DMD carriers. However, since this cellular defect does not consistently segregate with a single G6PD phenotype in the myoblast clones derived from any of the carriers, it is unlikely to be the primary expression of the DMD mutant allele.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3463532     DOI: 10.1007/BF00278789

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  23 in total

1.  THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS.

Authors:  L HAYFLICK
Journal:  Exp Cell Res       Date:  1965-03       Impact factor: 3.905

2.  Variability of red cell phenotypes between and within individuals in an unbiased sample of 77 heterozygotes for G6PD deficiency in Sardinia.

Authors:  A Rinaldi; G Filippi; M Siniscalco
Journal:  Am J Hum Genet       Date:  1976-09       Impact factor: 11.025

3.  Surface antigen differentiation during human myogenesis in culture.

Authors:  F S Walsh; M A Ritter
Journal:  Nature       Date:  1981-01-01       Impact factor: 49.962

4.  Evidence for defective myoblasts in Duchenne muscular dystrophy.

Authors:  H M Blau; C Webster; G K Pavlath; C P Chiu
Journal:  Adv Exp Med Biol       Date:  1985       Impact factor: 2.622

Review 5.  Duchenne muscular dystrophy. Genetic aspects, carrier detection and antenatal diagnosis.

Authors:  A E Emery
Journal:  Br Med Bull       Date:  1980-05       Impact factor: 4.291

6.  Defective myoblasts identified in Duchenne muscular dystrophy.

Authors:  H M Blau; C Webster; G K Pavlath
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

7.  Differentiation properties of pure populations of human dystrophic muscle cells.

Authors:  H M Blau; C Webster; C P Chiu; S Guttman; F Chandler
Journal:  Exp Cell Res       Date:  1983-04-01       Impact factor: 3.905

8.  Population genetics of haemoglobin variants, thalassaemia and glucose-6-phosphate dehydrogenase deficiency, with particular reference to the malaria hypothesis.

Authors:  M Siniscalco; L Bernini; G Filippi; B Latte; P Meera Khan; S Piomelli; M Rattazzi
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

9.  Isolation of mammalian cell mutants deficient in glucose-6-phosphate dehydrogenase activity: linkage to hypoxanthine phosphoribosyl transferase.

Authors:  M Rosenstraus; L A Chasin
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

10.  Characterization of glucose-6-phosphate dehydrogenase variants. I. Occurrence of a G6PD Seattle-like variant in Sardinia and its interaction with the G6PD Mediterranean variant.

Authors:  L Lenzerini; P Meera Khan; G Filippi; M C Rattazzi; A K Ray; M Siniscalco
Journal:  Am J Hum Genet       Date:  1969-03       Impact factor: 11.025

View more
  9 in total

1.  Isolation and characterization of human fetal myoblasts.

Authors:  Ariya D Lapan; Emanuela Gussoni
Journal:  Methods Mol Biol       Date:  2012

2.  Mental retardation in heterozygotes for the fragile-X mutation: evidence in favor of an X inactivation-dependent effect.

Authors:  M Rocchi; N Archidiacono; A Rinaldi; G Filippi; G Bartolucci; G S Fancello; M Siniscalco
Journal:  Am J Hum Genet       Date:  1990-04       Impact factor: 11.025

3.  Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice.

Authors:  Alessandra Sacco; Foteini Mourkioti; Rose Tran; Jinkuk Choi; Michael Llewellyn; Peggy Kraft; Marina Shkreli; Scott Delp; Jason H Pomerantz; Steven E Artandi; Helen M Blau
Journal:  Cell       Date:  2010-12-09       Impact factor: 41.582

4.  X-inactivation patch size in human female tissue confounds the assessment of tumor clonality.

Authors:  Marco Novelli; Antonio Cossu; Dahmane Oukrif; Alberto Quaglia; Sunil Lakhani; Richard Poulsom; Peter Sasieni; Piera Carta; Marcella Contini; Anna Pasca; Giuseppe Palmieri; Walter Bodmer; Francesco Tanda; Nick Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-27       Impact factor: 11.205

5.  Muscle glucose-6-phosphate dehydrogenase deficiency.

Authors:  N Bresolin; L Bet; M Moggio; G Meola; F Fortunato; G Comi; L Adobbati; L Geremia; S Pittalis; G Scarlato
Journal:  J Neurol       Date:  1989-05       Impact factor: 4.849

6.  Tumor necrosis factor inhibits human myogenesis in vitro.

Authors:  S C Miller; H Ito; H M Blau; F M Torti
Journal:  Mol Cell Biol       Date:  1988-06       Impact factor: 4.272

7.  Muscular dystrophy in the mdx mouse is a severe myopathy compounded by hypotrophy, hypertrophy and hyperplasia.

Authors:  William Duddy; Stephanie Duguez; Helen Johnston; Tatiana V Cohen; Aditi Phadke; Heather Gordish-Dressman; Kanneboyina Nagaraju; Viola Gnocchi; SiewHui Low; Terence Partridge
Journal:  Skelet Muscle       Date:  2015-05-01       Impact factor: 4.912

8.  Targeting muscle stem cell intrinsic defects to treat Duchenne muscular dystrophy.

Authors:  Nicolas A Dumont; Michael A Rudnicki
Journal:  NPJ Regen Med       Date:  2016-06-09

9.  CD133+ cells derived from skeletal muscles of Duchenne muscular dystrophy patients have a compromised myogenic and muscle regenerative capability.

Authors:  Jinhong Meng; Francesco Muntoni; Jennifer Morgan
Journal:  Stem Cell Res       Date:  2018-05-12       Impact factor: 2.020

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.